Retatrutide is often called a triple agonist because studies describe it acting on GLP-1, GIP, and glucagon receptors, while tirzepatide targets two of those pathways. The added glucagon receptor activity is the main structural difference researchers highlight, and investigation focuses on how it may influence energy expenditure alongside appetite signaling. Both remain the subject of ongoing clinical study rather than settled comparisons. This is general information, not medical advice; these compounds are prescription or research-only and are not approved for self-use in most countries. Do not source prescription drugs on this forum. Learn more: Retatrutide vs tirzepatide overview
Clear and to the point, nice.
The dual versus triple agonist distinction is helpful.